Researchers at Tunisia's Pasteur Institute have been studying genetic factors that may explain cognitive decline in some diabetes patients and their progression to Alzheimer's disease since 2023. The goal is to develop an early detection method for those most at risk and improve care. According to geneticist Dr. Rim Kafi, recent studies indicate that around 70% of diabetics are at risk of cognitive decline, increasing their likelihood of developing Alzheimer's.
Dr. Kafi presented findings at a scientific day organized by the City of Sciences in Tunis in collaboration with the Alzheimer's Association Tunisia. The event's theme was "Alzheimer's: Innovation, Prevention, and Support." The research team is working on understanding factors that make some diabetics more prone to cognitive decline and Alzheimer's, focusing on genetic factors linked to the disease's onset in this population.
The team is currently conducting a study involving 100 diabetes patient samples to identify scientific indicators that help understand the relationship between the two diseases. This will facilitate early detection of individuals most at risk of developing Alzheimer's. Dr. Kafi noted that the study is not yet complete and is expected to expand to include a larger number of diabetes patients, with final results anticipated in the coming years.
The research aims to pave the way for developing a blood test and genetic screening that can be conducted on diabetes patients to determine their susceptibility to Alzheimer's. This would enable early detection of disease-related indicators and timely intervention to slow its progression. According to experts, early detection of at-risk individuals can enhance prevention and health monitoring in the early stages.
The study's findings are expected to contribute to improved care and management of Alzheimer's disease in Tunisia. By identifying individuals at high risk, healthcare providers can offer targeted support and interventions to slow disease progression. The research team's efforts align with global initiatives to combat Alzheimer's through early detection and prevention.
Alzheimer's disease is a significant public health concern in Tunisia, with a growing number of cases expected in the coming years. The Pasteur Institute's research has the potential to make a substantial impact on the country's healthcare system by enabling early detection and intervention. The study's results will be crucial in informing healthcare policy and developing effective strategies for managing Alzheimer's.
The development of a blood test for early Alzheimer's detection in diabetics is a significant step forward in the fight against the disease. If successful, the test could be widely adopted in Tunisia and other countries, enabling healthcare providers to identify high-risk individuals and provide targeted support. The research team's work is an essential contribution to the global effort to combat Alzheimer's and improve public health.
Key points
- Researchers at Tunisia's Pasteur Institute are developing a blood test to detect Alzheimer's in diabetics.
- The test aims to identify individuals at high risk of developing Alzheimer's, enabling early intervention.
- The study's findings will contribute to improved care and management of Alzheimer's disease in Tunisia.
